Clinical-stage biopharmaceutical company NovaBridge Biosciences, formerly known as I-Mab, has released compelling updated Phase 1 data for its bispecific antibody candidate, givastomig. The complete dataset was presented in late October at the AACR-NCI-EORTC international conference, highlighting the drug’s performance in treating heavily pre-treated gastric cancer patients.
Clinical Results and Future Plans
Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, demonstrated an objective response rate of 18% in this challenging patient population. The disease control rate reached a notable 49%, with median progression-free survival recorded at 2.96 months and median overall survival at 7.49 months.
A significant finding from the trial reveals that treatment efficacy was consistent across various dose levels and CLDN18.2 expression thresholds. Researchers observed no new safety concerns or dose-limiting toxicities throughout the study period. The company has scheduled the initiation of a global randomized Phase 2 trial for givastomig during the first quarter of 2026.
Corporate Transformation and Listing Strategy
In a major strategic shift, the company completed a comprehensive rebranding effective October 30, 2025. Now operating as NovaBridge Biosciences, the firm trades on the Nasdaq exchange under the new ticker symbol NBP. This transformation establishes the biotechnology enterprise as a global platform for business development and clinical translation.
Should investors sell immediately? Or is it worth buying I-Mab?
The strategic repositioning extends beyond the name change. NovaBridge is pursuing a dual listing strategy with plans for an initial public offering on the Hong Kong Stock Exchange. This move would create simultaneous listings on both the Nasdaq and HKEX platforms, potentially broadening the company’s investor base and market presence.
Financial Position and Outlook
NovaBridge maintains substantial financial resources to support its operations and development pipeline. Through a signed capital increase completed in August 2025, the company secured net proceeds of approximately $61.2 million. When combined with existing funds, the pro-forma cash position as of June 30, 2025, totaled around $226.8 million.
This financial strength provides the organization with operational visibility through the fourth quarter of 2028. Investors will gain further insight into the company’s financial standing when NovaBridge reports its third-quarter 2025 results on November 13. These figures will reveal how recent corporate developments and clinical progress have impacted the balance sheet as the company positions itself for its next growth phase.
Ad
I-Mab Stock: Buy or Sell?! New I-Mab Analysis from February 7 delivers the answer:
The latest I-Mab figures speak for themselves: Urgent action needed for I-Mab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
I-Mab: Buy or sell? Read more here...
